钠-葡萄糖协同转运蛋白2抑制作用与胰岛素：胰高血糖素比值：未被探索的维度。
Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions.
作者信息
Kalra Sanjay, Gupta Yashdeep, Patil Shiva
机构信息
Department of Endocrinology, Bharti Hospital and B.R.I.D.E, Karnal, Haryana, India.
Department of Medicine, Government Medical College and Hospital, Chandigarh, India.
出版信息
Indian J Endocrinol Metab. 2015 May-Jun;19(3):426-9. doi: 10.4103/2230-8210.152793.
Abstract
The sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a novel class of glucose-lowering drugs which act by inhibiting the reabsorption of filtered glucose from the kidneys. Their effect on insulin and glucagon levels has recently been studied but is not fully explained. This communication proposes various hypotheses: A direct effect of SGLT-2 inhibition on the alpha cell receptors, a paracrine or intra-islet mediated effect on alpha cell sensitivity to glucose, and a calorie restriction mimetic action, to explain the impact of these drugs on the insulin glucagon ratio.
摘要
钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂是一类新型降糖药物，其作用机制是抑制肾脏对滤过葡萄糖的重吸收。最近对其对胰岛素和胰高血糖素水平的影响进行了研究，但尚未完全阐明。本通讯提出了各种假设：SGLT-2抑制对α细胞受体的直接作用、旁分泌或胰岛内介导的对α细胞对葡萄糖敏感性的作用，以及类似热量限制的作用，以解释这些药物对胰岛素与胰高血糖素比值的影响。
相似文献
1
Sodium-glucose cotransporter-2 inhibition and the insulin: Glucagon ratio: Unexplored dimensions.
Indian J Endocrinol Metab. 2015 May-Jun;19(3):426-9. doi: 10.4103/2230-8210.152793.
2
Metabolic effects of SGLT-2 inhibitors beyond increased glucosuria: A review of the clinical evidence.
Diabetes Metab. 2014 Dec;40(6 Suppl 1):S4-S11. doi: 10.1016/S1262-3636(14)72689-8.
3
Sodium-Glucose Cotransporter 2 Inhibitors: Possible Anti-Atherosclerotic Effects Beyond Glucose Lowering.
J Clin Med Res. 2016 Jan;8(1):10-4. doi: 10.14740/jocmr2385w. Epub 2015 Dec 3.
4
Ertugliflozin: a sodium-glucose cotransporter-2 (SGLT-2) inhibitor for glycemic control in type 2 diabetes.
Ther Clin Risk Manag. 2018 Sep 7;14:1637-1640. doi: 10.2147/TCRM.S137068. eCollection 2018.
5
Sodium-glucose Cotransporter 2 Inhibitors: Glucose Lowering Against other Hypoglycemic Agents.
Cardiovasc Hematol Disord Drug Targets. 2018;18(2):94-103. doi: 10.2174/1871529X18666180206160838.
6
Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Curr Med Res Opin. 2016 May;32(5):907-19. doi: 10.1185/03007995.2016.1151774. Epub 2016 Feb 26.
7
Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus.
J Clin Med Res. 2017 Sep;9(9):745-753. doi: 10.14740/jocmr3112w. Epub 2017 Jul 27.
8
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors: a new antidiabetic drug class.
Medchemcomm. 2018 Jun 6;9(8):1273-1281. doi: 10.1039/c8md00183a. eCollection 2018 Aug 1.
9
Sodium-glucose co-transporter 2 (SGLT2) inhibitors: a growing class of antidiabetic agents.
Drugs Context. 2014 Dec 19;3:212264. doi: 10.7573/dic.212264. eCollection 2014.
10
Sodium glucose co-transporter inhibitors - A new class of old drugs.
Int J Appl Basic Med Res. 2015 Sep-Dec;5(3):161-3. doi: 10.4103/2229-516X.165363.
引用本文的文献
1
Insulin:Glucagon Bipolar Axis in Obesity With a Glimpse Into Its Association With Insulin Resistance in Different Glucose Tolerance States.
Cureus. 2024 Apr 24;16(4):e58942. doi: 10.7759/cureus.58942. eCollection 2024 Apr.
2
Activation of G protein-coupled receptors by ketone bodies: Clinical implication of the ketogenic diet in metabolic disorders.
Front Endocrinol (Lausanne). 2022 Oct 20;13:972890. doi: 10.3389/fendo.2022.972890. eCollection 2022.
3
New Insights into the Role of Insulin and Hypothalamic-Pituitary-Adrenal (HPA) Axis in the Metabolic Syndrome.
Int J Mol Sci. 2022 Jul 25;23(15):8178. doi: 10.3390/ijms23158178.
4
Hyperinsulinemia and Its Pivotal Role in Aging, Obesity, Type 2 Diabetes, Cardiovascular Disease and Cancer.
Int J Mol Sci. 2021 Jul 21;22(15):7797. doi: 10.3390/ijms22157797.
5
Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
Indian J Endocrinol Metab. 2018 Jan-Feb;22(1):164-166. doi: 10.4103/ijem.IJEM_266_17.
6
Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.
Indian J Endocrinol Metab. 2017 Nov-Dec;21(6):909-918. doi: 10.4103/ijem.IJEM_85_17.
7
Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus.
Diabetes Metab Syndr Obes. 2017 May 2;10:161-167. doi: 10.2147/DMSO.S122767. eCollection 2017.
8
Safe and pragmatic use of sodium-glucose co-transporter 2 inhibitors in type 2 diabetes mellitus: South Asian Federation of Endocrine Societies consensus statement.
Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):210-230. doi: 10.4103/2230-8210.196029.
9
Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect.
Indian J Endocrinol Metab. 2016 Sep-Oct;20(5):725-729. doi: 10.4103/2230-8210.183826.
10
Adenosine monophosphate-activated protein kinase-based classification of diabetes pharmacotherapy.
J Postgrad Med. 2017 Apr-Jun;63(2):114-121. doi: 10.4103/0022-3859.191007.
本文引用的文献
1
Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial.
Lancet Diabetes Endocrinol. 2015 Jan;3(1):17-26. doi: 10.1016/S2213-8587(14)70226-8. Epub 2014 Nov 27.
2
SGLT inhibitors in management of diabetes.
Lancet Diabetes Endocrinol. 2013 Oct;1(2):140-51. doi: 10.1016/S2213-8587(13)70050-0. Epub 2013 Aug 13.
3
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
J Clin Invest. 2014 Feb;124(2):499-508. doi: 10.1172/JCI72227. Epub 2014 Jan 27.
4
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
J Clin Invest. 2014 Feb;124(2):509-14. doi: 10.1172/JCI70704. Epub 2014 Jan 27.
5
Metformin and the promise of geroprotection.
Indian J Endocrinol Metab. 2012 Jul;16(4):496-8. doi: 10.4103/2230-8210.97991.
6
Novel pharmacological approaches to the treatment of type 2 diabetes.
Pharmacol Rev. 2012 Apr;64(2):188-237. doi: 10.1124/pr.110.003319. Epub 2012 Mar 8.
7
Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.
Diabetes. 2009 Apr;58(4):773-95. doi: 10.2337/db09-9028.
8
Possible role of alpha-cell insulin resistance in exaggerated glucagon responses to arginine in type 2 diabetes.
Diabetes Care. 2007 Oct;30(10):2583-7. doi: 10.2337/dc07-0066. Epub 2007 Jul 20.
9
Stimulatory short-term effects of free fatty acids on glucagon secretion at low to normal glucose concentrations.
Metabolism. 2004 Nov;53(11):1443-8. doi: 10.1016/j.metabol.2004.06.011.
10
Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis.
Am J Physiol Endocrinol Metab. 2003 Aug;285(2):E438-46. doi: 10.1152/ajpendo.00057.2003. Epub 2003 Apr 8.
Zotero 插件